Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis

S. Stürzebecher, K. P. Wandinger, A. Rosenwald, M. Sathyamoorthy, A. Tzou, P. Mattar, J. A. Frank, L. Staudt, R. Martin, H. F. McFarland

Research output: Contribution to journalArticle

Abstract

Autoimmune diseases such as multiple sclerosis are characterized by complex genetic traits and pathomechanisms that translate into clinical heterogeneity. This wide heterogeneity of multiple sclerosis as well as different biological responses to immunomodulatory drugs can be expected to contribute to differential treatment responses. Strategies that dissect the relationship between the treatment response and the biological characteristics in individual patients are valuable not only as a clinical tool, but also in leading to a better understanding of the disease. Here we address the in vitro and ex vivo RNA expression profile under one approved therapy of multiple sclerosis, interferon-β (IFN-β, Betaseron), by cDNA microarrays and demonstrate that non-responder and responder phenotypes to IFN-β as assessed by longitudinal gadolinium-enhanced MRI scans and clinical disease activity differ in their ex vivo gene expression profile. These findings will help to better elucidate the mechanism of action of IFN-β in relation to different disease patterns and eventually lead to optimized therapy.

Original languageEnglish (US)
Pages (from-to)1419-1429
Number of pages11
JournalBrain
Volume126
Issue number6
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Interferons
Multiple Sclerosis
Phenotype
Gadolinium
Therapeutics
Oligonucleotide Array Sequence Analysis
Transcriptome
Autoimmune Diseases
Magnetic Resonance Imaging
RNA
Pharmaceutical Preparations

Keywords

  • cDNA microarrays
  • Expression profile
  • Interferon-β
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Stürzebecher, S., Wandinger, K. P., Rosenwald, A., Sathyamoorthy, M., Tzou, A., Mattar, P., ... McFarland, H. F. (2003). Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain, 126(6), 1419-1429. https://doi.org/10.1093/brain/awg147

Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. / Stürzebecher, S.; Wandinger, K. P.; Rosenwald, A.; Sathyamoorthy, M.; Tzou, A.; Mattar, P.; Frank, J. A.; Staudt, L.; Martin, R.; McFarland, H. F.

In: Brain, Vol. 126, No. 6, 01.06.2003, p. 1419-1429.

Research output: Contribution to journalArticle

Stürzebecher, S, Wandinger, KP, Rosenwald, A, Sathyamoorthy, M, Tzou, A, Mattar, P, Frank, JA, Staudt, L, Martin, R & McFarland, HF 2003, 'Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis', Brain, vol. 126, no. 6, pp. 1419-1429. https://doi.org/10.1093/brain/awg147
Stürzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P et al. Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain. 2003 Jun 1;126(6):1419-1429. https://doi.org/10.1093/brain/awg147
Stürzebecher, S. ; Wandinger, K. P. ; Rosenwald, A. ; Sathyamoorthy, M. ; Tzou, A. ; Mattar, P. ; Frank, J. A. ; Staudt, L. ; Martin, R. ; McFarland, H. F. / Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. In: Brain. 2003 ; Vol. 126, No. 6. pp. 1419-1429.
@article{e743d62e3c9f40aa87596a807e19f254,
title = "Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis",
abstract = "Autoimmune diseases such as multiple sclerosis are characterized by complex genetic traits and pathomechanisms that translate into clinical heterogeneity. This wide heterogeneity of multiple sclerosis as well as different biological responses to immunomodulatory drugs can be expected to contribute to differential treatment responses. Strategies that dissect the relationship between the treatment response and the biological characteristics in individual patients are valuable not only as a clinical tool, but also in leading to a better understanding of the disease. Here we address the in vitro and ex vivo RNA expression profile under one approved therapy of multiple sclerosis, interferon-β (IFN-β, Betaseron), by cDNA microarrays and demonstrate that non-responder and responder phenotypes to IFN-β as assessed by longitudinal gadolinium-enhanced MRI scans and clinical disease activity differ in their ex vivo gene expression profile. These findings will help to better elucidate the mechanism of action of IFN-β in relation to different disease patterns and eventually lead to optimized therapy.",
keywords = "cDNA microarrays, Expression profile, Interferon-β, Multiple sclerosis",
author = "S. St{\"u}rzebecher and Wandinger, {K. P.} and A. Rosenwald and M. Sathyamoorthy and A. Tzou and P. Mattar and Frank, {J. A.} and L. Staudt and R. Martin and McFarland, {H. F.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1093/brain/awg147",
language = "English (US)",
volume = "126",
pages = "1419--1429",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis

AU - Stürzebecher, S.

AU - Wandinger, K. P.

AU - Rosenwald, A.

AU - Sathyamoorthy, M.

AU - Tzou, A.

AU - Mattar, P.

AU - Frank, J. A.

AU - Staudt, L.

AU - Martin, R.

AU - McFarland, H. F.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Autoimmune diseases such as multiple sclerosis are characterized by complex genetic traits and pathomechanisms that translate into clinical heterogeneity. This wide heterogeneity of multiple sclerosis as well as different biological responses to immunomodulatory drugs can be expected to contribute to differential treatment responses. Strategies that dissect the relationship between the treatment response and the biological characteristics in individual patients are valuable not only as a clinical tool, but also in leading to a better understanding of the disease. Here we address the in vitro and ex vivo RNA expression profile under one approved therapy of multiple sclerosis, interferon-β (IFN-β, Betaseron), by cDNA microarrays and demonstrate that non-responder and responder phenotypes to IFN-β as assessed by longitudinal gadolinium-enhanced MRI scans and clinical disease activity differ in their ex vivo gene expression profile. These findings will help to better elucidate the mechanism of action of IFN-β in relation to different disease patterns and eventually lead to optimized therapy.

AB - Autoimmune diseases such as multiple sclerosis are characterized by complex genetic traits and pathomechanisms that translate into clinical heterogeneity. This wide heterogeneity of multiple sclerosis as well as different biological responses to immunomodulatory drugs can be expected to contribute to differential treatment responses. Strategies that dissect the relationship between the treatment response and the biological characteristics in individual patients are valuable not only as a clinical tool, but also in leading to a better understanding of the disease. Here we address the in vitro and ex vivo RNA expression profile under one approved therapy of multiple sclerosis, interferon-β (IFN-β, Betaseron), by cDNA microarrays and demonstrate that non-responder and responder phenotypes to IFN-β as assessed by longitudinal gadolinium-enhanced MRI scans and clinical disease activity differ in their ex vivo gene expression profile. These findings will help to better elucidate the mechanism of action of IFN-β in relation to different disease patterns and eventually lead to optimized therapy.

KW - cDNA microarrays

KW - Expression profile

KW - Interferon-β

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0038692013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038692013&partnerID=8YFLogxK

U2 - 10.1093/brain/awg147

DO - 10.1093/brain/awg147

M3 - Article

C2 - 12764062

AN - SCOPUS:0038692013

VL - 126

SP - 1419

EP - 1429

JO - Brain

JF - Brain

SN - 0006-8950

IS - 6

ER -